Sunday June 16, 2019
Home Lead Story Night Shifts ...

Night Shifts May Raise Risk Of Diabetes

For the study, published in the journal Diabetes Care, the team examined data from more than 270,000 people, including 70,000 who provided in-depth lifetime employment information and a sub-group of more than 44,000 for whom genetic data were available

0
//
The results showed that those with the highest genetic risk scores were almost four times as likely to develop Type 2 diabetes compared to individuals who had lower genetic risk scores. Pexels
The results showed that those with the highest genetic risk scores were almost four times as likely to develop Type 2 diabetes compared to individuals who had lower genetic risk scores. Pexels

Do you frequently work night shifts? Beware, you are more likely to develop Type 2 diabetes, a precursor to cardiovascular diseases, researchers have warned.

Type 2 diabetes is a chronic condition that affects the way the body processes blood sugar (glucose).

The study found that people working irregular or rotating shifts with usual night shifts were 44 percent more likely to have Type 2 diabetes.

ALSO READ: Night-owl women not for long-term relationships: Study

“We see a dose-response relationship between a frequency of night shift work and Type 2 diabetes, where the more often people do shift work, the greater their likelihood of having the disease, regardless of genetic predisposition,” said Ceiine Vetter, Professor at the University of Colorado-Boulder.

In addition, compared to day workers, all shift workers were more likely to have Type 2 diabetes, except for permanent night shift workers, the researchers mentioned. Pexels
In addition, compared to day workers, all shift workers were more likely to have Type 2 diabetes, except for permanent night shift workers, the researchers mentioned. Pexels

“This helps us understand one piece of the puzzle: frequency of night shift work seems to be an important factor,” Vetter added.

For the study, published in the journal Diabetes Care, the team examined data from more than 270,000 people, including 70,000 who provided in-depth lifetime employment information and a sub-group of more than 44,000 for whom genetic data were available.

ALSO READ: 6 Foods You Should Mandatorily Avoid At Night

More than 6,000 people in the sample population had Type 2 diabetes.

Using the information on more than 100 genetic variants that are associated with Type 2 diabetes, the research team developed a genetic risk score that they used to assign a value to each participant.

According to the World Health Organisation (WHO), the global prevalence of diabetes has nearly doubled since 1980, rising from 4.7 percent to 8.5 percent in the adult population. The majority of people with diabetes are affected by Type 2 diabetes. (IANS)

Next Story

Researchers Find Drug to Delay Type-1 Diabetes by Two Years

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine

0
Diabetes
Representational image. Pixabay

In a first, researchers have found that a treatment affecting the immune system effectively slowed the progression to clinical Type-1 diabetes in high risk individuals by two years or more.

“The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment,” said Lisa Spain, Project Scientist from US National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The study, involving treatment with an anti-CD3 monoclonal antibody (teplizumab), was conducted by Type 1 Diabetes TrialNet, an international collaboration aimed at discovering ways to delay or prevent Type-1 diabetes.

Participants were randomly assigned to either the treatment group, which received a 14-day course of teplizumab, or the control group, which received a placebo.

All participants received glucose tolerance tests regularly until the study was completed, or until they developed clinical Type-1 diabetes – whichever came first.

During the trial, 72 per cent of the people in the control group developed clinical diabetes, compared to only 43 per cent of the teplizumab group.

diabetes
“Although Type-1 and Type-2 diabetes in parents are well-established risk factors for diabetes, we show that gestational diabetes mellitus may be a risk indicator for diabetes in the mother’s children before age 22,” . Pixabay

The median time for people in the control group to develop clinical diabetes was just over 24 months, while those who developed clinical diabetes in the treatment group had a median time of 48 months before progressing to diagnosis.

“The difference in outcomes was striking. This discovery is the first evidence we’ve seen that clinical Type-1 diabetes can be delayed with early preventive treatment,” Spain added.

Type-1 diabetes develops when the immune system’s T cells mistakenly destroy the body’s own insulin-producing beta cells.

Also Read- Cutting Sodium Intake May Prevent 94 Million Premature Deaths From CVD

Insulin is needed to convert glucose into energy. Teplizumab targets T cells to lessen the destruction of beta cells.

The effects of the drug were greatest in the first year after it was given, said the study published online in The New England Journal of Medicine. (IANS)